Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.51 |
| ▸ | NOS1 | P29475 | 6/20 | 0.50 |
| ▸ | NOS2 | P35228 | 6/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.50 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.50 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6191572 | 1.00 | TAAR1 (0.51) | TAAR1NOS1NOS2GABRA1GABRR1 | |
| Hydrochloric Acid SCHEMBL6752220 | 0.98 | TAAR1 (0.50) | TAAR1NOS1NOS2GABRA1GABRR1 | |
| SCHEMBL6191375 | 0.84 | GABRA1 (0.45) | TAAR1NOS1NOS2GABRA1GABRR1 | |
| SCHEMBL6193169 | 0.84 | GABRA1 (0.45) | TAAR1NOS1NOS2GABRA1GABRR1 | |
| SCHEMBL27458720 | 0.83 | NOS1 (0.55) | TAAR1NOS1NOS2GABRA1GABRR1 | |
| SCHEMBL27458719 | 0.83 | NOS1 (0.55) | TAAR1NOS1NOS2GABRA1GABRR1 | |
| SCHEMBL27486545 | 0.83 | NOS1 (0.55) | TAAR1NOS1NOS2GABRA1GABRR1 | |
| SCHEMBL11358318 | 0.83 | NOS1 (0.47) | TAAR1NOS1NOS2GABRA1GABRR1 | |
| SCHEMBL6191222 | 0.83 | GABRA1 (0.47) | TAAR1NOS1NOS2GABRA1GABRR1 | |
| SCHEMBL6190236 | 0.83 | GABRA1 (0.47) | TAAR1NOS1NOS2GABRA1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003535853-A | — | — | 2003-12-02 | — | — | JP | claimed |
| EP-1299365-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | Aventis Pharma S.A. (FR) | 2003-04-09 | — | — | EP | claimed |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-12 | — | — | US | claimed |
| US-6451821-B1 | ADMINISTERING TO A PATIENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF 2-AMINOTHIAZOLINE DERIVATIVES FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH AN ABNORMAL PRODUCTION OF NITRIC OXIDE(NO) | AVENTIS PHARMA S.A. (FR) | 2002-09-17 | — | — | US | claimed |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2002-02-21 | — | — | US | claimed |
| WO-2001094325-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2001-12-13 | — | — | WO | claimed |
| US-11548862-B2 | Preparation method of selenium-containing heterocyclic compounds | WENZHOU UNIVERSITY (CN) | 2023-01-10 | — | — | US | disclosed |
| US-20220169623-A1 | PREPARATION METHOD OF SELENIUM-CONTAINING HETEROCYCLIC COMPOUNDS | WENZHOU UNIVERSITY (CN) | 2022-06-02 | — | — | US | disclosed |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-26 | — | — | US | disclosed |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-12 | — | — | US | disclosed |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548862-B2 | Preparation method of selenium-containing heterocyclic compounds | SCLY, TST, SOD1 | TAAR1 2250/4885NOS1 1254/4885NOS2 1005/4885 |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | NOS2, NOS3, NOS1 | TAAR1 369/4885NOS1 3/4885NOS2 1/4885 |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | NOS3, TH, CBR1 | TAAR1 276/4885NOS1 5/4885NOS2 4/4885 |
| US-20220169623-A1 | PREPARATION METHOD OF SELENIUM-CONTAINING HETEROCYCLIC COMPOUNDS | SCLY, TST, SOD1 | TAAR1 2250/4885NOS1 1254/4885NOS2 1005/4885 |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | NOS2, NOS3, NOS1 | TAAR1 348/4885NOS1 3/4885NOS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.